National Institute on Deafness and Other Communication Disorders (NIDCD)

Government

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

Acute Otitis Media: Adjuvant Therapy to Improve Outcome

Jul 14, 2026

Enrolling by invitation

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

Jul 11, 2026

Enrolling by invitation

Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan

Jul 9, 2026

Completed

Clinical and Molecular Analysis of Enlarged Vestibular Aqueducts

Jul 1, 2026

Recruiting

Normative Values in Audiovestibular Testing

Earlier

Jun 30, 2026TrialDeep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets

Jun 25, 2026TrialGenetic Analysis of Hereditary Disorders of Hearing and Balance

Jul 17, 2024TrialStudy of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

1 more events

Jul 10, 2024TrialAtorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)